Virginia Drake1, Elaine Bigelow1, Carole Fakhry1, Melina Windon1, Lisa M Rooper2, Patrick Ha3, Brett Miles4, Christine Gourin1, Rajarsi Mandal1, Wojciech Mydlarz1, Nyall London1, Peter S Vosler1, Siddhartha Yavvari5, Tanya Troy5, Tim Waterboer6, David W Eisele1, Gypsyamber D'Souza7. 1. Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, MD, United States. 2. Department of Pathology, Johns Hopkins University, Baltimore, MD, United States. 3. Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, United States. 4. Department of Otolaryngology-Head and Neck Surgery, Mount Sinai Health System, New York City, NY, United States. 5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. 6. Infections and Cancer Epidemiology, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany. 7. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States. Electronic address: gdsouza2@jhu.edu.
Abstract
OBJECTIVES: Tumor HPV status is an established independent prognostic marker for oropharynx cancer (OPC). Recent studies have reported that tumor estrogen receptor alpha (ERα) positivity is also associated with prognosis independent of HPV. Little is known about the biologic and behavioral predictors of ERα positivity in head and neck squamous cell cancer (HNSCC). We therefore explored this in a multicenter prospective cohort study. MATERIALS AND METHODS: Participants with HNSCC completed a survey and provided a blood sample. Tumor samples were tested for ERα using immunohistochemistry. ERα positivity was defined as ≥1%, standardized by the American Society of Clinical Oncology/College of American Pathologists in breast cancer. Characteristics were compared with χ2 and Fisher's exact test. Odds ratios (OR) were calculated using logistic regression. RESULTS: Of 318 patients with HNSCC, one third had ERα positive tumors (36.2%, n = 115). Odds of ERα expression were significantly increased in those with HPV-positive tumors (OR = 27.5, 95% confidence interval[CI] 12.1-62), smaller tumors (≤T2, OR = 3.6, 95% CI 1.9-7.1), male sex (OR = 2.0, 95% CI 1.1-3.6), overweight/obesity (BMI ≥ 25, OR = 1.9, 95% CI 1.1-3.3), and those married/living with a partner (OR = 1.7, 95% CI 1.0-3.0). In a multivariate model, HPV-positivity (aOR = 27.5, 95% CI 11.4-66) and small tumor size (≤T2, aOR = 2.2, 95% CI 1.0-4.8) remained independently associated with ERα status. When restricted to OPC (n = 180), tumor HPV status (aOR = 17.1, 95% CI 2.1-137) and small tumor size (≤T2, aOR = 4.0 95% CI 1.4-11.3) remained independently associated with ERα expression. CONCLUSION: Tumor HPV status and small tumor size are independently associated with ERα expression in HNSCC.
OBJECTIVES: Tumor HPV status is an established independent prognostic marker for oropharynx cancer (OPC). Recent studies have reported that tumor estrogen receptor alpha (ERα) positivity is also associated with prognosis independent of HPV. Little is known about the biologic and behavioral predictors of ERα positivity in head and neck squamous cell cancer (HNSCC). We therefore explored this in a multicenter prospective cohort study. MATERIALS AND METHODS: Participants with HNSCC completed a survey and provided a blood sample. Tumor samples were tested for ERα using immunohistochemistry. ERα positivity was defined as ≥1%, standardized by the American Society of Clinical Oncology/College of American Pathologists in breast cancer. Characteristics were compared with χ2 and Fisher's exact test. Odds ratios (OR) were calculated using logistic regression. RESULTS: Of 318 patients with HNSCC, one third had ERα positive tumors (36.2%, n = 115). Odds of ERα expression were significantly increased in those with HPV-positive tumors (OR = 27.5, 95% confidence interval[CI] 12.1-62), smaller tumors (≤T2, OR = 3.6, 95% CI 1.9-7.1), male sex (OR = 2.0, 95% CI 1.1-3.6), overweight/obesity (BMI ≥ 25, OR = 1.9, 95% CI 1.1-3.3), and those married/living with a partner (OR = 1.7, 95% CI 1.0-3.0). In a multivariate model, HPV-positivity (aOR = 27.5, 95% CI 11.4-66) and small tumor size (≤T2, aOR = 2.2, 95% CI 1.0-4.8) remained independently associated with ERα status. When restricted to OPC (n = 180), tumor HPV status (aOR = 17.1, 95% CI 2.1-137) and small tumor size (≤T2, aOR = 4.0 95% CI 1.4-11.3) remained independently associated with ERα expression. CONCLUSION: Tumor HPV status and small tumor size are independently associated with ERα expression in HNSCC.
Authors: Tim Waterboer; Peter Sehr; Kristina M Michael; Silvia Franceschi; John D Nieland; Thomas O Joos; Markus F Templin; Michael Pawlita Journal: Clin Chem Date: 2005-08-11 Impact factor: 8.327
Authors: M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff Journal: Arch Pathol Lab Med Date: 2010-07 Impact factor: 5.534
Authors: S Kondo; K Wakae; N Wakisaka; Y Nakanishi; K Ishikawa; T Komori; M Moriyama-Kita; K Endo; S Murono; Z Wang; K Kitamura; T Nishiyama; K Yamaguchi; S Shigenobu; M Muramatsu; T Yoshizaki Journal: Oncogene Date: 2016-10-03 Impact factor: 9.867
Authors: Gulam Nabi Sofi; Junaid Nabi Sofi; Raja Nadeem; Rayees Yousuf Shiekh; Faroze Ahmad Khan; Abid Ahmad Sofi; Hillal Ahmad Bhat; Rayees Ahmad Bhat Journal: Asian Pac J Cancer Prev Date: 2012
Authors: Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Justine M Ritchie; Elaine M Smith; Kurt F Summersgill; Henry T Hoffman; Donghong Wang; Jens P Klussmann; Lubomir P Turek; Thomas H Haugen Journal: Int J Cancer Date: 2003-04-10 Impact factor: 7.396
Authors: P Boscolo-Rizzo; A Del Mistro; F Bussu; V Lupato; L Baboci; G Almadori; M C DA Mosto; G Paludetti Journal: Acta Otorhinolaryngol Ital Date: 2013-04 Impact factor: 2.124